1.17% Dividend Yield, 16 Years of Dividend Hikes – A Medical Device Powerhouse With Surgical Scale And Consistent Innovation
This is the kind of healthcare business that makes money by being deeply embedded in operating rooms, trauma centers, and hospital supply chains, which is a pretty good place to be when you want recurring demand and a lot of repeat customers. It sells everything from orthopedic implants and surgical instruments to neurotechnology and med-surg equipment, so the company is not betting on one product cycle or one therapeutic trend; it is spread across the plumbing of modern care. That diversification gives it a durable growth engine, and the best part is that the industry keeps replacing its own equipment, which is the corporate version of making sure the lights stay on.
Stryker (SYK)
Financial Score: 98 / 99
Quick Tip
To keep your portfolio strong, stay on top of the financials for each company you hold. Solid companies mean better returns, so be sure to check in on their quarterly and annual numbers.Interesting stocks usually score 80+ on the Financial Scale, with top players hitting 90+. If that score dips below 80, it might be a good time to consider cutting ties before things take a turn.Stryker (SYK) is a Kalamazoo, Michigan-based medical technology company with operations across the U.S. and international markets, focused on orthopedics, medical and surgical equipment, neurotechnology, and spine products. Its portfolio reaches hospitals, ambulatory surgery centers, and specialty clinics, where it supplies tools that clinicians use every day rather than once in a blue moon. Over time, it has grown into one of the most recognizable medtech franchises in the world, built on a mix of acquisitions, product launches, and steady investment in innovation.
Dividend engine: a low-yield name with room to grow
Stryker pays $3.52 per share annually, which gives it a 1.17% yield and a 40.74% payout ratio, so the dividend is clearly being treated as a growth-friendly commitment rather than a cash drain. The company has raised the payout for 16 consecutive years, and its 5-year dividend growth rate of +44.00% shows that management has been comfortable letting the dividend grow alongside the business. That fits the medtech profile nicely: you want a payout that stays out of the way of R&D and acquisitions, and Stryker’s coverage leaves plenty of room for both. It is not the kind of dividend that screams for attention, but it is the kind that quietly compounds while the product pipeline keeps doing its job.
Q1 2026: sales grew, but a cyber hit muddied the quarter
For the first quarter of 2026, reported April 30, Stryker posted net sales of $6.0 billion, up 2.6% year over year, with organic sales growth of 2.4% and adjusted EPS of $2.60. The company also reported operating margin of 15.5% and adjusted operating margin of 21.1%, which tells you the core business was still producing healthy economics even though a late-quarter cyber incident disrupted some revenue timing and pressured results. In other words, the quarter was not perfect, but the underlying demand backdrop was still solid enough that management held full-year guidance for organic sales growth of 8.5% and adjusted EPS of $14.90 to $15.10.
Growth levers: new products, portfolio breadth, and procedure volume
Stryker’s growth story is still mostly about doing more in the places hospitals already spend money. The company continues to lean on new products, especially in orthopedics and surgical tools, while also expanding its presence in high-volume care settings where procedure counts matter more than headline drama. That broad footprint gives it a lot of ways to win: implant volume, instrument refresh cycles, and adjacent equipment sales all feed the same machine. Even after the cyber-related disruption, management pointed to strong underlying demand and kept the long-term growth framework intact, which suggests the franchise still has enough momentum to absorb a bump in the road without losing the bigger picture.
How a medtech company became a compounding habit
The interesting thing about Stryker is that it sits in a category where customers do not buy for fun; they buy because the products are tied to patient outcomes, workflow efficiency, and surgeon preference. That creates a nice kind of stickiness, because once a hospital standardizes on systems, instruments, and implant families, switching becomes more complicated than just swapping a supplier. Add in the fact that Stryker has spent decades building brand trust in specialties where reliability matters, and you get a business that behaves a lot like an operating habit for healthcare providers. That is a very good place to be when you want repeat business and pricing power without having to shout about it.
Final Take – A medtech compounder that still has plenty of runway
Stryker offers a 1.17% yield, $3.52 annual dividend, 40.74% payout ratio, 16 years of dividend hikes, and +44.00% five-year dividend growth, all supported by a business that keeps finding ways to sell into the everyday machinery of healthcare. Q1 2026 delivered $6.0 billion in sales, $2.60 adjusted EPS, 15.5% operating margin, and 21.1% adjusted operating margin, while management left full-year guidance intact despite the cyber noise. Financial Score: 98. That is firmly in elite territory: the dividend is well covered, the growth profile is still attractive, and the company’s depth across hospitals and surgical workflows gives it a moat that feels more practical than flashy, which is usually where the best long-term stories hide.
Someone’s sitting in the shade today because someone planted a tree a long time ago. ― Warren Buffett.
Learn the MaxDividends Way
Start Here
🔑 Explore the Premium Hub (exclusive — upgrade to unlock)
Guides & Step-by-Step
Deep Insights
📖 I ❤️ Dividends: Why I Believe Dividend Investing Is the Best Strategy | E-Book
How Effective is the MaxDividends Strategy for Building Growing Passive Income
Help & Support
Got a question about dividends? Ask Max, your AI Dividend Assistant!
Didn’t get the answer you need? Reach out: max@maxdividends.app or team@maxdividends.app — we’ll help you out.